Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
13.22 USD +4.75% Intraday chart for Evolus, Inc. +15.36% +25.55%
Apr. 26 AbbVie raises annual profit forecast on strong Skyrizi sales RE
Apr. 17 Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evolus to Report First Quarter Financial Results on May 7, 2024
BU
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
BU
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results, Reaffirms 2024 Guidance
AQ
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
BU
Evolus Announces Results from European Head-to-Head Filler Trial
AQ
Evolus Announces Results from European Head-to-Head Filler Trial
BU
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
BU
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations, Issues 2024 Guidance
AQ
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
BU
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.
  5. Press Releases